Palisade Bio Inc. (PALI) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, PALI scores 43 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 9/20 (ROIC of -35%; FCF yield of -5.23%); Whale 13F Flow at 9/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 12/20 (beta of 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 2.5; Piotroski F of 2/9; Debt/Equity of 0.5). For a prospective investor, the weakest pillars are insider conviction and the cash engine. The fundamental pillar reflects negative return on invested capital and negative free cash flow yield, meaning the company is not currently generating cash returns on the capital deployed. The forensic pillar is middling rather than distressed, with a Piotroski score of 2 out of 9 signaling weak fundamental quality. Upside drivers cited in the source data are limited to the news flow and institutional activity noted below; the rating itself frames the near-term setup as vulnerable. Valuation tradeoffs cannot be assessed on earnings because P/E and EPS are not available in source data. This analysis is educational and is not personalized financial advice.

Palisade Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company carries a market capitalization of $0.2B. The source data does not describe its specific products, customers, or revenue model. Reported revenue is $0.0M in FY 2025 and FY 2024 and $0.2M in FY 2023, per the SEC financials.

Per the SEC financials, the company reported operating losses in each period shown, with margins of 0% across gross, operating, and net measures per the market data. ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, both as referenced in the Roarable RQD rating. Reported cash rose to $133.4M in FY 2025 from $9.8M in FY 2024, and debt is listed as N/A in the filings provided, with a Debt/Equity ratio of 0.5 per the RQD rating.

Per the recent news and catalysts feed, the flow is headline-driven and includes the following items:

• A report that a gut inflammation marker fell 58.8% in five patients after 14 days on the company's experimental drug (Stock Titan), flagged YELLOW.
• An H.C. Wainwright reiteration of a buy rating on the stock (Investing.com), flagged YELLOW.
• A grant of 787,300 stock units to Counsel, subject to service-based vesting (Stock Titan), flagged YELLOW.
• A Simply Wall St item titled as a US$26m market cap fall with insider losses, flagged RED under RISK WATCH.
• General market-wire coverage from Yahoo Finance Singapore and Simply Wall St, flagged YELLOW.

The RED risk-watch item concerns insider losses following the market cap decline. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

• What products or pipeline assets does the company hold, and what stage are they at?
• What are the terms and timing of the cash position reported at $133.4M in FY 2025, given cash of $9.8M in FY 2024?
• What is the debt structure behind the Debt/Equity ratio of 0.5, given that debt is listed as N/A?
• What is the size and timing of the insider losses and stock-unit grants referenced in the news feed?
• What is the company's current cash runway relative to its negative free cash flow?